NIH StrokeNet Professional Development Seminar – Dec 4, 2018

When and How to Consult with a Statistician…etc

Yuko Y. Palesch, PhD
Department of Public Health Sciences
Medical University of South Carolina

Conflict of Interest / Disclaimer

- I am one of the multiple PIs of the StrokeNet National Data Management Center (NDMC) in Charleston, SC.
- This presentation contains my personal biases and opinions.

StrokeNet NDMC in Charleston, SC

Medical University of South Carolina (MUSC)

↓

College of Medicine (COM)

↓

Department of Public Health Sciences (DPHS)

↓

Data Coordination Unit (DCU)*

* Whence, the database software name, WebDCU™.

DCU Biostatistics Team


Dr. Yeatts


Dr. Palesch


Dr. Martin


Dr. Meinzer


Dr. Elm


Dr. Durkalski


Dr. Zhao


Ms. Foster


Ms. Pauls


Ms. Underwood


Ms. Gottfried


Ms. Teklehaimanot

World's View of Statisticians



Traditionally (Pre-2015)

Today

THE WALL STREET JOURNAL.

EDUCATION

UC Berkeley's Fastest-Growing Class Is Data Science 101

The university has created a division to study the science of mining the tidal wave of digital information that floods our lives. More than 300 universities offer some type of data major at a time when companies like Google can't hire enough specialists

11/19/2018

"Sexiest Job of the 21st Century"





"Big" Data Scientists vs Statisticians

Data Scientist ≠ (clinical trials) Statistician



Aside: Big Data – Quality vs Quantity



"Twitter and Facebook can't predict the election, but they did predict what you're going to have for lunch: a tuna salad sandwich. You're having the wrong sandwich."

- Be careful about using survey and registry data without understanding how the data were collected and cleaned (or not).
- Be careful about "meta-analysis" using patient level data – make sure you are concatenating apples and apples – example of "baseline" NIHSS in IMS 3 vs MR CLEAN in the context of IV-tPA treatment timing.
- You can show statistical significance if you have large enough N – be cautious of over-powered analysis that has no clinical value.

(Clinical Trials) Statistical Collaboration

Do NOT think that:

- Anyone with just some statistics courses will do.
- You only need a statistician at the beginning (to give you the necessary sample size) and at the end (to do the analyses).
- You don't need to include them as authors, especially if you pay them.



Do consider to:

- Find a statistician sooner than later - http://www.youtube.com/watch?v=Hz1fyhVOjr4
- Find a statistician who is familiar with (or at least with interest to learn about) your clinical area.
- Find a statistician who has clinical trials experiences – not just design and/or analysis, but in the actual implementation (like finding an architect who has actually "built" a structure).

Where to Find a Clinical Trials Statistician?

- Ask your mentors and colleagues at your institution.
- Inquire with biostatistics departments or groups (e.g., CTSA) at your institution.
- Browse through published papers of clinical trials designs and/or results.
- Contact someone who has taught you a clinical trials course, like instructors at the NINDS-sponsored Clinical Trials Methodology Course.
- Ask NINDS.
- Ask NDMC or other DCCs.

How to Work with a Clinical Trial Statistician?

- In-person meeting is the best, at least at the beginning.
- Agree early on about expectations – role in the grant (e.g., co-PI or co-I), order of authorship in the papers, funding/financial issues, timeline, etc.
- Keep the ball moving… You ask for input, you get it, and then, not get back in touch for months is problematic (yes, it's a two-way street).
- Communicate regularly!
  - Ask questions until you understand the design/methods.
  - Keep the statistician in the loop on all aspects of the project.
  - Include them in the interpretation of analysis results.
- Remember, he/she is on your team as a collaborator.

Some Random Statistical Issues in a Nutshell

- Study designs
- Sample size calculations
- P-values vs alpha levels
- Grant writing and budgeting

Study Designs

Adaptive Designs (ADs)

- Purpose - often useful for Phase II trials when there're still many uncertainties about the intervention – best for exploratory/phase II studies.
- Adaptive Designs ≠ smaller sample size, nor is it necessarily efficient.
- Frequent looks at the data may be vulnerable to unblinding, biases, etc.
- Implementation can be a real 
- Use gingerly for Phase III trials – don't make it so complicated such that it makes the study results difficult to interpret.
- Keep publication efforts in mind when designing ADs.

Futility Designs



- Purpose – to ascertain whether a treatment is worth moving forward to a Phase III assessment for its effectiveness, i.e., to rule out a complete dud.
- Futility designs should be for an exploratory, Phase II stage of a drug/treatment development.
- Not to be confused with "futility analysis" in a Phase III trial (or even in a Phase II trial).

Non-Inferiority Designs

- Purpose – to ascertain whether a new treatment is as effective as (or no worse than) the currently available treatment.
- Must have an active control (with or without a placebo control).
- Usually a very large Phase III stage trial.
- Must define and quantify "margin of non-inferiority" – NOT the same as MCID.
- Analyses are often based on confidence intervals.

Sample Size Estimation



Statisticians Need to know…

- Primary scientific hypothesis.
- Study design.
- Primary outcome measure and its statistical characteristics under the H_0 (e.g., distribution, mean, sd, etc), aka control group's presumed data.
- MCID - minimum clinical important difference, i.e., ***effect size***, you want to see that could <u>lead to changing clinical practice</u>.

NOTE: effect size is not a statistical issue.

Statisticians Need to know…

- **Type I (α)** and **Type II (β)** error *probabilities* – know their interpretation under your hypothesis setting (e.g., superiority, non-inferiority, futility), and the consequences of committing these errors.
  - α = Pr [reject H_0 | H_0 is true]
  - β = Pr [fail to reject H_0 | H_A is true]
- Smaller the values of α and β, the larger the sample size.

In a superiority study setting:



α error = **false positive** error

β error = **false negative** error

Choice of the Alpha Level

Does α have to be 0.05 (2-sided) or 0.025 (1-sided)? (NOTE: β can generally range from 0.1 to 0.2)?



- Treatment that is not expensive with few side effects…
- Treatment for a condition that has no remedy or cure…
- Treatment to be tested in a Phase II stage, using futility design…
- Treatment that is very promising but moderately toxic and expensive…

Note: These same thought process can/should be applied to the choice of MCID.

P-values


Researchers
and the Holy Grail
P<0.05
© 1974 National Film Trustee Company Limited. All Rights Reserved. Python (Monty) Pictures, Ltd.
© 2006 Layout and Design Sony Pictures Home Entertainment Inc. All Rights Reserved.

P-values

- Definition of ***p***-value: The probability of observing treatment effect (e.g., group difference in mean response) as extreme or more extreme (away from the H_0) if the H_0 is true. Hence, the smaller the ***p***-value, the more extreme or rare the observed data are, given the H_0 to be true.
- ***p*-values are premised on the condition specified in the null hypothesis, as is the α value**

- The ***p***-value obtained from the data is judged against the α. (NOTE: Remember that p-values and α are not the same thing.)
- If the p-value < pre-specified α, then the data suggest that the study result is so rare under the H_0 that lead us to question the veracity of condition specified in the null hypothesis; hence, we reject the H_0.

P-values



- Suppose for a study with a pre-specified α =0.05, the result was p=0.09, i.e., could not reject H_0.
- Note that "failure to reject H_0" does not prove that the treatment groups are equal with respect to the outcome, i.e., you don't "accept H_0".
- Don't say, "There was no difference in the treatment groups…", unless your hypotheses were set up to prove this (e.g., equivalence design).
- Put the research hypothesis that you want to prove in the alternative.

Grant Writing with a Statistician



Grant Writing and Budgeting (for NDMC)

- **DON'T procrastinate!**
- If you are relatively new to grant writing, strongly recommend having an experienced mentor. StrokeNet (NCC, NDMC, WGs) also can help.
- Get the draft of the near-final Specific Aims and Research Strategy sections ASAP to the statistician – tough for statistician to write his/her section in a vacuum.
- FYI - Items included in the NDMC budget for StrokeNet trials include:
  - Personnel Effort (Statisticians, DMs, PMs, Programmers, Neuroimaging Managers);
  - Travel;
  - Supplies; and
  - **On-Site Monitoring costs (a big ticket item).**
- NDMC moving more towards remote monitoring to save on travel costs, and to central monitoring (by DMs and statisticians) to reduce on-site monitoring time.

Thank you for your attention!